Genotoxic potential of porphyrin type photosensitizers with particular emphasis on 5-aminolevulinic acid: implications for clinical photodynamic therapy.
Photodynamic therapy (PDT) uses exogenously administered photosensitizers activated by light to induce cell death or modulation of immunological cascades, presumably via formation of reactive oxygen species (ROS). 5-Aminolevulinic acid (ALA) mediated photosensitization is increasingly used for the treatment of nonmelanoma skin cancer and other indications including benign skin disorders. Long-term side effects of this investigational modality are presently unknown. Just as tumor treatments such as ionizing radiation and chemotherapy can cause secondary tumor induction, PDT may potentially have a carcinogenic risk. Evaluation of the biological effects of ALA in absence of activating light and analysis of the mechanism of ALA-PDT and porphyrin-type photosensitizers mediated photosensitization indicate that this therapy has a pro-oxidant and genotoxic potential. However, porphyrin type molecules also possess antioxidant and antimutagenic properties. ALA-PDT delays photocarcinogenesis in mice, and topical ALA alone does not increase skin cancer incidence in these animals. Patients with increased tissue levels of ALA have an increased incidence of internal carcinoma, however, it is not clear whether this relationship is casual or causal. There is no evidence indicating higher rates of skin cancer in patients with photosensitivity diseases due to presence of high protoporphyrin IX (PP) levels in skin. Overall, the presently available data indicate that the risk for secondary skin carcinoma after topical ALA-PDT seems to be low, but further studies must be carried out to evaluate the carcinogenic risk of ALA-PDT in conditions predisposed to skin cancer.
Fuchs
J
J
Department of Dermatology, Medical School, J. W. Goethe University, Frankfurt, Germany.
Weber
S
S
Kaufmann
R
R
D000622:Aminolevulinic Acid / Q000633:toxicity*; D000818:Animals; D002273:Carcinogens / Q000633:toxicity; D006801:Humans; D051379:Mice; D009153:Mutagens / Q000633:toxicity*; D009369:Neoplasms / Q000139:chemically induced; D010778:Photochemotherapy / Q000009:adverse effects; D017319:Photosensitizing Agents / Q000633:toxicity*; D011166:Porphyrins / Q000633:toxicity*
D002273:Carcinogens; D009153:Mutagens; D017319:Photosensitizing Agents; D011166:Porphyrins; D000622:Aminolevulinic Acid